Matthew D. Coates
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew D. Coates has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Shannon Dalessio
Division of Gastroenterology and Hepatology
20 shared publicationsAugust Stuart
Division of Gastroenterology and Hepatology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USA
13 shared publicationsAndrew Tinsley
Division of Gastroenterology and Hepatology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USA
11 shared publications- Kofi Clarke
Department of Medicine, Division of Gastroenterology and Hepatology, Penn State Health Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, PA 17033, USA
7 shared publications Vonn Walter
Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA
7 shared publicationsWalter Koltun
Department of Surgery, Division of Colorectal Surgery, Pennsylvania State University College of Medicine, Hershey, USA
7 shared publications
Latest Publications
- Open Access
- 24 December 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (6) , 1-7
Analgesic Management of Chronic Pancreatitis
Abdominal pain is the most prevalent symptom of chronic pancreatitis and, when inadequately controlled, it leads to impaired quality of life across physical, psychological, and social domains, along with increased healthcare utilization and reduced life expectancy. Effective pain control remains challenging due to the multifactorial and complex etiology of pain, yet it is essential for improving patient outcomes. An accurate pain assessment using validated clinical tools is a critical first step toward optimizing management. Effective treatment often requires a multidisciplinary, multimodal approach that integrates lifestyle modifications, including smoking and alcohol cessation, with stepwise pharmacologic therapy. For patients with refractory pain, surgical and endoscopic interventions are viable treatment options. This review provides a comprehensive overview of non-pharmacologic, pharmacologic, endoscopic, and surgical strategies for managing painful chronic pancreatitis, emphasizing evidence-based approaches that improve patient outcomes.
- 24 December 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (6) , 1-7
Open AccessAnalgesic Management of Chronic Pancreatitis
Abdominal pain is the most prevalent symptom of chronic pancreatitis and, when inadequately controlled, it leads to impaired quality of life across physical, psychological, and social domains, along with increased healthcare utilization and reduced life expectancy. Effective pain control remains challenging due to the multifactorial and complex etiology of pain, yet it is essential for improving patient outcomes. An accurate pain assessment using validated clinical tools is a critical first step toward optimizing management. Effective treatment often requires a multidisciplinary, multimodal approach that integrates lifestyle modifications, including smoking and alcohol cessation, with stepwise pharmacologic therapy. For patients with refractory pain, surgical and endoscopic interventions are viable treatment options. This review provides a comprehensive overview of non-pharmacologic, pharmacologic, endoscopic, and surgical strategies for managing painful chronic pancreatitis, emphasizing evidence-based approaches that improve patient outcomes.
- 5 November 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
Opioid Provision After Inpatient Care is Associated With Poor Outcomes in Inflammatory Bowel Disease
Goals: In this study, we investigate clinical outcomes of inflammatory bowel disease (IBD) patients prescribed opioids after discharge from the hospital or emergency department (ED). Background: IBD is commonly associated with abdominal pain. Opioids are frequently prescribed to address pain in IBD patients. Importantly, however, there is limited evidence of analgesic benefit. In addition, there are significant safety concerns about opioid use in this setting. Study: This retrospective study utilized Merative MarketScan claims databases to identify IBD patients who had a hospital or ED visit between 2017 and 2021. Two patient groups were formed based on whether they received an opioid prescription within 7 days of discharge or not. Demographics and baseline clinical features were evaluated. Using χ 2 tests and logistic regression, clinical outcomes were compared between groups at 3 time points (1, 3, and 6 mo) starting 7 days after discharge. Results: Thirty-five thousand eight hundred ninety IBD patients were included in the analysis, with 7892 (22.0%) patients in the opioid prescription group. Using logistic regression analysis, IBD opioid users were found to be significantly more likely to experience repeat ED visits, hospitalizations and opioid prescriptions at multiple time points. IBD opioid users were also more likely to receive corticosteroids and undergo medication escalation during follow-up. Ulcerative colitis opioid users also trended toward being more likely to undergo IBD-associated surgery 6 months after discharge. Conclusions: Patients who are prescribed opioids after acute hospital care are more likely to have poor clinical outcomes. Physicians should avoid prescribing opioids to IBD patients at discharge from the ED or hospital.
- 5 November 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
Opioid Provision After Inpatient Care is Associated With Poor Outcomes in Inflammatory Bowel Disease
Goals: In this study, we investigate clinical outcomes of inflammatory bowel disease (IBD) patients prescribed opioids after discharge from the hospital or emergency department (ED). Background: IBD is commonly associated with abdominal pain. Opioids are frequently prescribed to address pain in IBD patients. Importantly, however, there is limited evidence of analgesic benefit. In addition, there are significant safety concerns about opioid use in this setting. Study: This retrospective study utilized Merative MarketScan claims databases to identify IBD patients who had a hospital or ED visit between 2017 and 2021. Two patient groups were formed based on whether they received an opioid prescription within 7 days of discharge or not. Demographics and baseline clinical features were evaluated. Using χ 2 tests and logistic regression, clinical outcomes were compared between groups at 3 time points (1, 3, and 6 mo) starting 7 days after discharge. Results: Thirty-five thousand eight hundred ninety IBD patients were included in the analysis, with 7892 (22.0%) patients in the opioid prescription group. Using logistic regression analysis, IBD opioid users were found to be significantly more likely to experience repeat ED visits, hospitalizations and opioid prescriptions at multiple time points. IBD opioid users were also more likely to receive corticosteroids and undergo medication escalation during follow-up. Ulcerative colitis opioid users also trended toward being more likely to undergo IBD-associated surgery 6 months after discharge. Conclusions: Patients who are prescribed opioids after acute hospital care are more likely to have poor clinical outcomes. Physicians should avoid prescribing opioids to IBD patients at discharge from the ED or hospital.
- Open Access
- 28 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6095
Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model
Background: Ulcerative colitis (UC) is an autoimmune disorder characterized by inflammation of the mucosa that gives rise to a disrupted epithelial morphology. Persistent or recurrent inflammation and the debilitating nature of the associated symptoms make treatment of UC challenging. Cannabinoids derived from Cannabis sativa L. have been used for treatment of gastrointestinal disorders due to the wide-ranging therapeutic benefits of these compounds. Methods: We evaluated a commercial hemp extract, high in cannabigerol (CBG) and cannabidiol (CBD), as a novel treatment for UC symptoms using the dextran sodium sulfate (DSS) model in mice. Hemp extract was administered via two different routes of administration, intraperitoneal (i.p) and oral (p.o). Results: Specifically, we observed that cannabinoid treatment reduced damage to the colonic epithelium. We also observed that CBG/CBD rich hemp extracts help reduce pain-related responses in these animals. Conclusions: Together, the data suggest that cannabinoid administration has the potential to be an effective alternate therapeutic option for UC management.
- 28 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6095
Open AccessOrally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model
Background: Ulcerative colitis (UC) is an autoimmune disorder characterized by inflammation of the mucosa that gives rise to a disrupted epithelial morphology. Persistent or recurrent inflammation and the debilitating nature of the associated symptoms make treatment of UC challenging. Cannabinoids derived from Cannabis sativa L. have been used for treatment of gastrointestinal disorders due to the wide-ranging therapeutic benefits of these compounds. Methods: We evaluated a commercial hemp extract, high in cannabigerol (CBG) and cannabidiol (CBD), as a novel treatment for UC symptoms using the dextran sodium sulfate (DSS) model in mice. Hemp extract was administered via two different routes of administration, intraperitoneal (i.p) and oral (p.o). Results: Specifically, we observed that cannabinoid treatment reduced damage to the colonic epithelium. We also observed that CBG/CBD rich hemp extracts help reduce pain-related responses in these animals. Conclusions: Together, the data suggest that cannabinoid administration has the potential to be an effective alternate therapeutic option for UC management.
- 11 July 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 62 (5) , 545-546
Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
- 11 July 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 62 (5) , 545-546
Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
- 21 May 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (6) , 103593
Better together? Individual and synergistic effects of noneuphorigenic cannabinoids on visceral sensation
- 21 May 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (6) , 103593
Better together? Individual and synergistic effects of noneuphorigenic cannabinoids on visceral sensation
- 8 May 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 62 (1) , 99-100
Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
- 8 May 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 62 (1) , 99-100
Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
- 11 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (12) , 1944-1956
The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study
Background: Patients with inflammatory bowel disease (IBD) are often prescribed antispasmodics for chronic abdominal pain. Large‐scale data regarding efficacy and impact on clinical outcomes are lacking.Aim: To examine the association between antispasmodic use and outcomes of abdominal pain and opioid use before and after propensity matching key demographic and clinical characteristics.Methods: We used TriNetX Diamond Network, a medical and claims database. Patients were stratified by baseline abdominal pain and opioid use. Secondary outcomes were corticosteroid use, IBD‐related complications and surgeries, emergency room (ER) visits, hospitalisation and mortality.Results: We included 85,859 patients (median age 50; 53.8% female) with IBD; 5661 used antispasmodics. On follow‐up, those with antispasmodic use had higher rates of abdominal pain and opioid use (p < 0.001) regardless of baseline abdominal pain or opioid use. After matching, 5629 patients remained per group. Patients who used antispasmodics had higher rates of abdominal pain at 1 month, regardless of baseline abdominal pain. Opioid‐naïve patients who used antispasmodics had higher rates of opioid use at follow‐up (1.1% vs. 0.2%; p < 0.001). The likelihood of corticosteroid use, clinic visits, ER visits and hospitalisation were higher in those with antispasmodic use. No differences in IBD‐related complications, surgery or mortality were observed.Conclusions: Antispasmodic use in patients with IBD was associated with increased abdominal pain and opioid use in opioid‐naïve patients. Antispasmodic use was associated with increased likelihood of corticosteroid use, clinic and ER visits and hospitalisation.
- 11 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (12) , 1944-1956
The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study
Background: Patients with inflammatory bowel disease (IBD) are often prescribed antispasmodics for chronic abdominal pain. Large‐scale data regarding efficacy and impact on clinical outcomes are lacking.Aim: To examine the association between antispasmodic use and outcomes of abdominal pain and opioid use before and after propensity matching key demographic and clinical characteristics.Methods: We used TriNetX Diamond Network, a medical and claims database. Patients were stratified by baseline abdominal pain and opioid use. Secondary outcomes were corticosteroid use, IBD‐related complications and surgeries, emergency room (ER) visits, hospitalisation and mortality.Results: We included 85,859 patients (median age 50; 53.8% female) with IBD; 5661 used antispasmodics. On follow‐up, those with antispasmodic use had higher rates of abdominal pain and opioid use (p < 0.001) regardless of baseline abdominal pain or opioid use. After matching, 5629 patients remained per group. Patients who used antispasmodics had higher rates of abdominal pain at 1 month, regardless of baseline abdominal pain. Opioid‐naïve patients who used antispasmodics had higher rates of opioid use at follow‐up (1.1% vs. 0.2%; p < 0.001). The likelihood of corticosteroid use, clinic visits, ER visits and hospitalisation were higher in those with antispasmodic use. No differences in IBD‐related complications, surgery or mortality were observed.Conclusions: Antispasmodic use in patients with IBD was associated with increased abdominal pain and opioid use in opioid‐naïve patients. Antispasmodic use was associated with increased likelihood of corticosteroid use, clinic and ER visits and hospitalisation.
- 18 December 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (2) , 462-468
Asymptomatic Erosive Esophagitis
Gastroesophageal reflux disease (GERD) is a very common condition characterized by chronic symptoms, such as heartburn or epigastric and/or substernal pain, that are frequently associated with mucosal damage resulting from abnormal reflux of gastric contents into the esophagus (Fass et al. in Nat Rev Dis Primers 7:55, 2021; Richter and Rubenstein in Gastroenterology 154:267–276, 2018). However, this damage can manifest in patients who do not exhibit typical GERD symptoms. Asymptomatic erosive esophagitis (AEE) is a condition in which there is esophageal mucosal injury typical for GERD, such as erosions, ulcerations, and/or Barrett’s esophagus, visible in upper endoscopy, without concurrent symptoms attributable to GERD. AEE has been challenging to study, and it is not yet clear what causes this condition. As a result, there are no definitive guidelines on how to manage it. AEE also has the potential to be very impactful on public health, as those who are affected may go years without a diagnosis, putting them at risk for a variety of complications, including strictures and even cancer. Further careful study is necessary in order to more effectively address this condition. Here, we provide a comprehensive review of the scientific literature regarding AEE, examining its prevalence, clinical characteristics, potential causes and contributing factors, as well as identifying avenues for better characterization and management of this patient population.
- 18 December 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (2) , 462-468
Asymptomatic Erosive Esophagitis
Gastroesophageal reflux disease (GERD) is a very common condition characterized by chronic symptoms, such as heartburn or epigastric and/or substernal pain, that are frequently associated with mucosal damage resulting from abnormal reflux of gastric contents into the esophagus (Fass et al. in Nat Rev Dis Primers 7:55, 2021; Richter and Rubenstein in Gastroenterology 154:267–276, 2018). However, this damage can manifest in patients who do not exhibit typical GERD symptoms. Asymptomatic erosive esophagitis (AEE) is a condition in which there is esophageal mucosal injury typical for GERD, such as erosions, ulcerations, and/or Barrett’s esophagus, visible in upper endoscopy, without concurrent symptoms attributable to GERD. AEE has been challenging to study, and it is not yet clear what causes this condition. As a result, there are no definitive guidelines on how to manage it. AEE also has the potential to be very impactful on public health, as those who are affected may go years without a diagnosis, putting them at risk for a variety of complications, including strictures and even cancer. Further careful study is necessary in order to more effectively address this condition. Here, we provide a comprehensive review of the scientific literature regarding AEE, examining its prevalence, clinical characteristics, potential causes and contributing factors, as well as identifying avenues for better characterization and management of this patient population.
- Open Access
- 17 October 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (12) , e00778
Impact of SCN10A Polymorphism on Abdominal Pain Perception and Visceral Hypoalgesia in Crohn's Disease and Ulcerative Colitis
INTRODUCTION: Hypoalgesic inflammatory bowel disease (IBD) may provide critical insights into human abdominal pain. This condition was previously associated with homozygosity for a polymorphism (rs6795970, A1073V; 1073val/val) related to Nav1.8, a voltage-gated sodium channel preferentially expressed on nociceptors. It was unclear whether this relationship existed for both Crohn's disease (CD) and ulcerative colitis (UC). This study evaluated a larger, carefully phenotyped IBD cohort to investigate this question. METHODS: Allelic and genotypic frequencies of rs6795970 were compared among study cohorts characterized by concomitant assessment of intestinal inflammatory status and abdominal pain experience. Visceral sensory perception was performed in healthy individuals using rectal balloon distension. RESULTS: We analyzed 416 patients with IBD (261CD:155UC) and 142 healthy controls. In the IBD cohort, 84 individuals (43CD:41UC) were determined to have hypoalgesic disease. The allelic frequency of rs6795970 was significantly higher in patients with hypoalgesic IBD when compared with other patients with IBD and healthy controls. Patients with hypoalgesic IBD were also more likely to be homozygous for this polymorphism when compared with other patients with IBD and healthy controls. Hypoalgesic CD (30% vs 12%, P = 0.004) and hypoalgesic UC (32% vs 15%, P = 0.036) were each significantly more likely to be associated with homozygosity for the rs6795970 polymorphism. In a cohort of healthy individuals (n = 50), rs6795970 homozygotes (n = 11) also demonstrated reduced abdominal discomfort to rectal balloon distension. DISCUSSION: These findings indicate that Nav1.8 plays a key role in human visceral pain perception, and could serve as a novel diagnostic target in the management of hypoalgesic CD and UC, and potential therapeutic target for conditions associated with chronic abdominal pain.
- 17 October 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (12) , e00778
Open AccessImpact of SCN10A Polymorphism on Abdominal Pain Perception and Visceral Hypoalgesia in Crohn's Disease and Ulcerative Colitis
INTRODUCTION: Hypoalgesic inflammatory bowel disease (IBD) may provide critical insights into human abdominal pain. This condition was previously associated with homozygosity for a polymorphism (rs6795970, A1073V; 1073val/val) related to Nav1.8, a voltage-gated sodium channel preferentially expressed on nociceptors. It was unclear whether this relationship existed for both Crohn's disease (CD) and ulcerative colitis (UC). This study evaluated a larger, carefully phenotyped IBD cohort to investigate this question. METHODS: Allelic and genotypic frequencies of rs6795970 were compared among study cohorts characterized by concomitant assessment of intestinal inflammatory status and abdominal pain experience. Visceral sensory perception was performed in healthy individuals using rectal balloon distension. RESULTS: We analyzed 416 patients with IBD (261CD:155UC) and 142 healthy controls. In the IBD cohort, 84 individuals (43CD:41UC) were determined to have hypoalgesic disease. The allelic frequency of rs6795970 was significantly higher in patients with hypoalgesic IBD when compared with other patients with IBD and healthy controls. Patients with hypoalgesic IBD were also more likely to be homozygous for this polymorphism when compared with other patients with IBD and healthy controls. Hypoalgesic CD (30% vs 12%, P = 0.004) and hypoalgesic UC (32% vs 15%, P = 0.036) were each significantly more likely to be associated with homozygosity for the rs6795970 polymorphism. In a cohort of healthy individuals (n = 50), rs6795970 homozygotes (n = 11) also demonstrated reduced abdominal discomfort to rectal balloon distension. DISCUSSION: These findings indicate that Nav1.8 plays a key role in human visceral pain perception, and could serve as a novel diagnostic target in the management of hypoalgesic CD and UC, and potential therapeutic target for conditions associated with chronic abdominal pain.
- 3 October 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (12) , 2531-2532
Response to the Letter to the Editor, “Refining the Understanding of Cannabis Impact on Inflammatory Bowel Disease Outcomes: Recommendations for Enhanced Research and Healthcare Practices”
To the Editors, We appreciate the opportunity to respond to the comments submitted by Guo et al. regarding our recent article.1 In brief, we agree with several concerns or suggestions that they shared in their letter. For example, they point out a number of potential methodological shortcomings associated with our article, including the lack of detailed data regarding cannabinoid dosing characteristics and the limitations of relying upon ICD-10 and CPT codes for data abstraction. We highlighted the latter point in our “Discussion” section, and certainly agree that incorporation of data relating to cannabis type and administration (as possible) should be an important consideration in future studies focused on this topic. We also appreciate the suggestion about incorporating imputation techniques and sensitivity analyses to help fill in potential “gaps” of data in the event that studies utilizing similar data sets are undertaken in the future. There were other points made in the letter from Guo et al. that we do not necessarily agree with. Specifically, they suggest that the database relied upon for this study (ie, the TriNetX Diamond Network) “may not capture the full diversity of IBD patients.” It is not particularly clear what this statement is based on. We agree with the concept and importance of using a larger and progressively more representative source of data. There are certainly limitations to what can be abstracted from this resource (as outlined above). However, the network and database in question currently represent one of the largest and most comprehensive sources of information in the world for population-based studies and include data from a wide variety of healthcare centers located around the world.2 In addition, it is difficult to assess (or certainly act upon) this type of comment without having specific alternative resources for comparison. Finally, Guo et al. recommend that healthcare providers develop “emergency response plans and educational programs” focused on cannabis-related complications for individuals with IBD. We wholeheartedly agree with the concept of educating patients and healthcare providers about cannabis in the context of IBD. However, we would caution the readers about drawing too many firm conclusions about the relative safety profile of cannabis in this setting. To be clear, we are not advocating for specific health care approaches based on the results of this study. The only conclusion we shared at the end of this paper is that this topic warrants further, careful study. This is all the more important due to the varied and occasionally conflicting findings of this and previous studies on this subject, making it very challenging to draw firm conclusions or develop clear clinical guidelines as of yet.3-5
- 3 October 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (12) , 2531-2532
Response to the Letter to the Editor, “Refining the Understanding of Cannabis Impact on Inflammatory Bowel Disease Outcomes: Recommendations for Enhanced Research and Healthcare Practices”
To the Editors, We appreciate the opportunity to respond to the comments submitted by Guo et al. regarding our recent article.1 In brief, we agree with several concerns or suggestions that they shared in their letter. For example, they point out a number of potential methodological shortcomings associated with our article, including the lack of detailed data regarding cannabinoid dosing characteristics and the limitations of relying upon ICD-10 and CPT codes for data abstraction. We highlighted the latter point in our “Discussion” section, and certainly agree that incorporation of data relating to cannabis type and administration (as possible) should be an important consideration in future studies focused on this topic. We also appreciate the suggestion about incorporating imputation techniques and sensitivity analyses to help fill in potential “gaps” of data in the event that studies utilizing similar data sets are undertaken in the future. There were other points made in the letter from Guo et al. that we do not necessarily agree with. Specifically, they suggest that the database relied upon for this study (ie, the TriNetX Diamond Network) “may not capture the full diversity of IBD patients.” It is not particularly clear what this statement is based on. We agree with the concept and importance of using a larger and progressively more representative source of data. There are certainly limitations to what can be abstracted from this resource (as outlined above). However, the network and database in question currently represent one of the largest and most comprehensive sources of information in the world for population-based studies and include data from a wide variety of healthcare centers located around the world.2 In addition, it is difficult to assess (or certainly act upon) this type of comment without having specific alternative resources for comparison. Finally, Guo et al. recommend that healthcare providers develop “emergency response plans and educational programs” focused on cannabis-related complications for individuals with IBD. We wholeheartedly agree with the concept of educating patients and healthcare providers about cannabis in the context of IBD. However, we would caution the readers about drawing too many firm conclusions about the relative safety profile of cannabis in this setting. To be clear, we are not advocating for specific health care approaches based on the results of this study. The only conclusion we shared at the end of this paper is that this topic warrants further, careful study. This is all the more important due to the varied and occasionally conflicting findings of this and previous studies on this subject, making it very challenging to draw firm conclusions or develop clear clinical guidelines as of yet.3-5